WHO decision challenges West to recognize Chinese vaccines


In this Monday, May 17, 2021 file photo, a passenger of a flight arriving at Faro leaves the airport, outside Faro, in Portugal's southern Algarve region. The World Health Organization said that any COVID-19 vaccines it has authorized for emergency use should be recognized by countries as they open up their borders, in a move that could challenge Western countries to broaden their acceptance of two Chinese vaccines which the U.N. health agency has licensed, but most European and North American countries have not. (AP Photo/Ana Brigida, File)

GENEVA (AP) — The World Health Organization said Thursday that any COVID-19 vaccines it has authorized for emergency use should be recognized by countries as they open up their borders to inoculated travelers.

The move could challenge Western countries to broaden their acceptance of two apparently less effective Chinese vaccines, which the U.N. health agency has licensed but most European and North American countries have not.

In addition to vaccines by Pfizer-BioNTech, Moderna Inc., AstraZeneca and Johnson & Johnson, the WHO has also given the green light to the two Chinese jabs, made by Sinovac and Sinopharm.

In its aim to restore travel across Europe, the European Union said in May that it would only recognize people as vaccinated if they had received shots licensed by the European Medicines Agency — although it’s up to individual countries if they wish to let in travelers who have received other vaccines, including Russia’s Sputnik V.

The EU drug regulator is currently considering licensing China's Sinovac vaccine, but there is no timeline on a decision. It also does not recognize versions of the AstraZeneca vaccine that were made in India, effectively barring travel for people in developing countries who received doses via the U.N.-backed initiative known as COVAX.

“Any measure that only allows people protected by a subset of WHO-approved vaccines to benefit from the reopening of travel ... would effectively create a two-tier system, further widening the global vaccine divide and exacerbating the inequities we have already seen in the distribution of COVID-19 vaccines,” a WHO statement said Thursday. “It would negatively impact the growth of economies that are already suffering the most.”

The WHO said such moves undermine "confidence in life-saving vaccines that have already been shown to be safe and effective.” In its reviews of the two Chinese vaccines, the U.N. health agency said both were found to significantly reduce the risk of hospitalizations and deaths.


The two Chinese shots are “inactivated” vaccines, made with killed coronavirus, whereas the Western-made shots are made with newer technologies that instead target the “spike” protein that coats the surface of the coronavirus.

Although Western countries have largely relied on vaccines made in the U.S. and Europe, such as Pfizer-BioNTech and AstraZeneca, many developing countries have used the Chinese-made shots.

Earlier this year, the head of China’s Center for Disease Control and Prevention acknowledged the effectiveness of its home-grown shots was low. Numerous countries that have used millions of doses of the two Chinese shots, including the Seychelles and Bahrain, have seen COVID-19 surges even with relatively high levels of immunization.

___

Follow all of AP’s pandemic coverage at https://apnews.com/hub/coronavirus-pandemic, https://apnews.com/hub/coronavirus-vaccine and https://apnews.com/UnderstandingtheOutbreak

Should you invest $1,000 in Moderna right now?

Before you consider Moderna, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Moderna wasn't on the list.

While Moderna currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Johnson & Johnson (JNJ)
4.908 of 5 stars
$146.82-1.2%3.24%9.15Hold$175.86
Moderna (MRNA)
4.0176 of 5 stars
$106.18-2.5%N/A-8.56Hold$126.49
Compare These Stocks  Add These Stocks to My Watchlist 


Featured Articles and Offers

Johnson & Johnson's Dip is a Strategic Buy Point for Investors

Johnson & Johnson's Dip is a Strategic Buy Point for Investors

JNJ shares hit a low, trading near $145 at under 14X earnings. With a high dividend yield, it's poised for a rebound.

Search Headlines: